Judo Bio

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months Dr. Ravi Thadhani, internationally recognized nephrology leader

The post American Society of Nephrology Kidney Week The STRIKE Platform Enables Kidney-Selective Gene Silencing via Megalin-Mediated Uptake appeared first on Judo Bio.

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months Dr. Ravi Thadhani, internationally recognized nephrology leader

Judo Bio Inc. has announced preclinical data demonstrating that its megalin-STRIKER oligonucleotide therapeutics achieved robust and sustained, kidney cell-selective gene silencing in rodents and nonhuman primates (NHPs).

In vivo studies demonstrate robust and durable gene silencing across rodents and non-human primates

In vivo studies demonstrate robust and durable gene silencing across rodents and non-human primates Megalin-targeting ligand-siRNA conjugates (megalin-STRIKERs) deliver siRNAs to proximal tubular epithelial cells (PTECs) in the kidney leading to target ge

The post 21 st Annual Meeting of the Oligonucleotide Therapeutics Society The STRIKE Platform Enables Kidney-Selective Gene Silencing via Megalin-Mediated Uptake appeared first on Judo Bio.

CAMBRIDGE, Mass., September 19, 2025 - Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivery to the kidney, today announced that it has been named as one of the Endpoints 11 most promising private biotechnology companies of 2025.